A detailed history of Syncona Portfolio LTD transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Syncona Portfolio LTD holds 16,640,720 shares of AUTL stock, worth $32.4 Million. This represents 73.83% of its overall portfolio holdings.

Number of Shares
16,640,720
Previous 18,554,624 10.31%
Holding current value
$32.4 Million
Previous $67.4 Million 41.94%
% of portfolio
73.83%
Previous 83.42%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

SELL
$2.18 - $4.8 $4.17 Million - $9.19 Million
-1,913,904 Reduced 10.31%
16,640,720 $39.1 Million
Q3 2024

Nov 14, 2024

SELL
$3.38 - $4.69 $9.44 Million - $13.1 Million
-2,792,205 Reduced 13.08%
18,554,624 $67.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $24.4 Million - $45.8 Million
14,000,000 Added 190.56%
21,346,829 $40.6 Million
Q4 2021

Feb 11, 2022

BUY
$5.1 - $7.0 $37.5 Million - $51.4 Million
7,346,829 New
7,346,829 $38.1 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $177M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Syncona Portfolio LTD Portfolio

Follow Syncona Portfolio LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syncona Portfolio LTD, based on Form 13F filings with the SEC.

News

Stay updated on Syncona Portfolio LTD with notifications on news.